Background Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-
2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers …

The clinical presentation of COVID-19 is very heterogeneous, ranging from asymptomatic to
severe, which could lead to the need for mechanical ventilation or even death. We analyzed …

Objective To delineate the characteristics and clinical significance of plasma inflammatory
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …

Objectives An excessive inflammatory response to SARS-CoV-2 is thought to be a major
cause of disease severity in COVID-19. The aim herein was to determine the prognostic …

The severity of COVID-19 is largely determined by the inflammatory response, a “Cytokine
storm,” that involves both pro-and anti-inflammatory cytokines. In the current study we …

Background: Biomarkers that would help prognosticate outcomes and guide treatment of
patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed …

Objective Cytokine release syndrome is suggested to be the most important mechanism
triggering acute respiratory distress syndrome and end organ damage in COVID-19. The …

Introduction Coronavirus disease 2019 (COVID-19) appeared in China in December 2019
and has spread around the world. High Interleukin-6 (IL-6) levels in COVID-19 patients …

Introduction and aim Interleukin-6 to lymphocyte (IL-6/Lym) ratio has been identified as a
potential prognostic tool in patients with SARS-CoV2 related pneumonia. The aim of our …

Immunity with SARS-CoV-2 infection during the acute phase is not sufficiently well
understood to differentiate mild from severe cases and identify prognostic markers. We …